

Review

# Neural Stem Cells: What Happens When They Go Viral?

Yashika S. Kamte, Manisha N. Chandwani, Alexa C. Michaels and Lauren A. O'Donnell \* 

Graduate School of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA; kamtey@duq.edu (Y.S.K.); chandwanim@duq.edu (M.N.C.); michaela@duq.edu (A.C.M.)

\* Correspondence: odonnell6@duq.edu; Tel.: +1-412-396-5133

**Abstract:** Viruses that infect the central nervous system (CNS) are associated with developmental abnormalities as well as neuropsychiatric and degenerative conditions. Many of these viruses such as Zika virus (ZIKV), cytomegalovirus (CMV), and herpes simplex virus (HSV) demonstrate tropism for neural stem cells (NSCs). NSCs are the multipotent progenitor cells of the brain that have the ability to form neurons, astrocytes, and oligodendrocytes. Viral infections often alter the function of NSCs, with profound impacts on the growth and repair of the brain. There are a wide spectrum of effects on NSCs, which differ by the type of virus, the model system, the cell types studied, and the age of the host. Thus, it is a challenge to predict and define the consequences of interactions between viruses and NSCs. The purpose of this review is to dissect the mechanisms by which viruses can affect survival, proliferation, and differentiation of NSCs. This review also sheds light on the contribution of key antiviral cytokines in the impairment of NSC activity during a viral infection, revealing a complex interplay between NSCs, viruses, and the immune system.

**Keywords:** neural stem cells; viruses; proliferation; survival; neurogenesis; differentiation; gliogenesis; cell death; cytokines



**Citation:** Kamte, Y.S.; Chandwani, M.N.; Michaels, A.C.; O'Donnell, L.A. Neural Stem Cells: What Happens When They Go Viral? *Viruses* **2021**, *13*, 1468. <https://doi.org/10.3390/v13081468>

Academic Editors: Sara Salinas and Muriel Couplier

Received: 24 May 2021  
Accepted: 28 June 2021  
Published: 27 July 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Viral infections in the central nervous system (CNS) are capable of inducing long-term neurological damage, particularly when the immune response fails to fully resolve the infection. Neurotropic viruses can alter the activity of infected neural cells and even lead to cell death. Neural stem cells (NSCs) are the pluripotent stem cells of the brain, and they are vulnerable to infection by numerous neurotropic viruses [1–7]. NSCs have the ability to both “self-renew” through symmetric cell division and to differentiate into neurons and glial cells. Both of these functions are critical to building the developing brain in pre- and post-natal periods and to maintain physiological function and responses to injury within select regions of the adult brain [8]. NSC proliferation and differentiation is governed by a finely orchestrated series of signals, which when disrupted can result in dysfunction in the development of neural circuits [9]. Thus, diseases that disturb physiological NSC activity can have lifelong consequences, particularly when they occur during key stages of neurodevelopment [10].

Viruses interrupt stem cell function in different ways, depending upon the virus and age of the host. The vulnerability of NSCs to viral infections is often age-dependent, with the younger population displaying more profound effects [10]. The older population does not remain immune to changes in NSC activity, since NSCs in the adult neurogenic niches (e.g., hippocampus and subventricular zone (SVZ)) undergo neurogenesis to govern memory and olfaction [8,11–14]. However, we are only beginning to understand the viral and host factors that modulate NSC activity. NSCs may be directly infected by viruses, leading to changes in commitment to other cell types and potentially cell death. NSCs can also be affected by cytokines and chemokines that are released as part of the antiviral immune response [15–17]. It has been complicated to dissect the contribution of the viral


infection and the antiviral immune response in mediating NSC activity, but recent *in vitro* and *in vivo* studies have shed light onto how NSCs respond to viruses. In this review, we will focus on the consequences of viral infections of NSCs and the associated outcomes on survival, proliferation, and differentiation.

## 2. NSC Survival and Proliferation


NSCs undergo periods of extensive cell division in order to maintain the NSC pool, and disruptions in proliferation at critical periods in development can lead to an extended loss of NSCs (Figure 1A). Reduction of the NSC pool can limit long-term neurogenesis, which is associated with the development of neurodegenerative diseases and deficits in adult learning and memory [18,19]. NSCs can be depleted due to multiple, non-exclusive mechanisms, including inhibited proliferation, increased cell death, and/or greater commitment to other cell lineages. Viral infections such as Zika virus (ZIKV), herpes simplex virus-1 (HSV-1), lymphocytic choriomeningitis virus (LCMV), and Japanese encephalitis virus (JEV) are associated with a range of neurological outcomes including microcephaly, blindness/hearing loss, memory deficits, and cognitive decline, respectively [3,20–25]. Although these viruses vary in terms of cellular tropism and disease course, they are also associated with disruptions in NSC activity, which has implications for life-long neurogenesis in the brain (Figure 1A) [26–28]. The underlying mechanisms driving the loss of NSCs remain largely undefined; however, clues are beginning to emerge from the literature.

Reduced proliferation can lead to a depletion of the NSC pool. Viruses may inhibit proliferation by blocking specific stages of the cell cycle and/or modulation of proteins that control self-renewal (Table 1). Many *in vitro* models of NSC infection (e.g., ZIKV-MR766, cytomegalovirus (CMV), JEV, and human immunodeficiency virus (HIV)) are associated with DNA damage and cell cycle arrest in the S-phase (DNA synthesis phase) of the cell cycle [1,29–33]. During JEV infection, reduced NSC proliferation may also be accompanied with increased neurogenesis, which could further reduce the NSC pool. Some viruses interfere with the expression of NSC-specific regulatory proteins that are required for maintaining a proliferative state. CMV infection of human NSCs suppresses Hes1 expression, which is an important protein for governing NSC cell fate choice and proliferation [34,35]. NSC treatment with HIV tat protein results in nuclear localization of the E3-ubiquitin ligase tripartite containing motif 32 (TRIM-32) protein, accumulation of which is associated with reduced NSC proliferation and increased neurogenesis. These *in vitro* findings were confirmed in autopsy samples of HIV-seropositive individuals, where reduced NSC numbers were accompanied by increased TRIM-32 nuclear localization in the remaining NSCs [36]. These studies indicate there are multiple mechanisms via which viral infections might lead to reduced NSC proliferation.

## A. Disruption of physiological maintenance of NSC pool during a viral infection



## B. Alteration of NSC differentiation during a viral infection



**Figure 1.** Effects of viral infections on the physiological functions of NSCs. Under physiological conditions, NSCs can proliferate via symmetric cell division to maintain the NSC pool. Viral infections such as ZIKV and CMV can deplete the NSC pool by inducing apoptosis or reducing proliferation of NSCs (A) Based upon tightly coordinated developmental cues, NSCs undergo differentiation to yield neurons, astrocytes, or oligodendrocytes. Viral infections can result in aberrant differentiation of NSCs, with many viruses leading to reduced neurogenesis (B) Some viruses, such as CMV and JEV, can inhibit both neurogenesis and gliogenesis. ZIKV impacts differentiation in a strain-dependent manner; the ZIKV Brazilian strain (BR\_ZIKV\_AB\_ES) reduced neurogenesis whereas ZIKV French Polynesian strain (H/PF/2013) and ZIKV American strain (FB-GWUH-2016) increased the number of cells expressing a neuronal marker (Tuj1). Viruses can also affect the formation of glia, with many viruses blocking astroglialogenesis and ZIKV African strain (IB H 30656) blocking the formation of oligodendrocytes.

NSC numbers can also be depleted due to apoptosis. Numerous viruses such as CMV, JEV, LCMV, West Nile virus (WNV), Usutu virus (USUV), enterovirus 71 (EV71), and Cocksackie B virus (CVB3) induce apoptosis in NSCs [30–32,37–41]. Both intrinsic and extrinsic apoptosis pathways can be activated during viral infection [32,42]. CMV and JEV infection induces apoptosis via activation of the MAP-Kinase (MAPK) pathways and the unfolded protein response (UPR) activation, which are triggered through endoplasmic reticulum (ER) stress [4,32,42]. Viral infections can induce ER stress possibly due to the utilization of ER proteins required for immediate early viral replication and translation [43,44].

Whether a virus induces apoptosis or inhibits proliferation may be influenced, in part, by the choice of model system. HSV-1 infection of monolayer cultures results in cell death of the majority of the NSCs [45]. However, HSV-1 infection of NSCs in cerebral organoids or 3D cultures induced mild cell death despite increased expression of genes associated with apoptosis [46]. These variations in NSC survival highlight the importance of considering multiple NSC models for investigating interactions with viruses, including those that recapitulate elements of the neural microenvironment.

Although many viruses are associated with apoptosis in NSCs, the extent of cell death versus cell cycle blockade can be dependent on the strain of the virus [27,47]. ZIKV infections can be associated with multiple effects on NSCs (Figure 1A), which may be partially attributed to differences in viral replication. For instance, ZIKV MR766 and IBH 30656 (African strains) yield high concentrations of viral proteins during infection of human cells, whereas ZIKV PRVABC59 and H/PF/2013 (Asian strains) result in undetectable protein concentrations soon after ZIKV infection [48]. The African ZIKV strains have been shown to cause higher mortality and severe neurological complications in comparison to the Asian ZIKV strains [49]. The ZIKV Paraiba Brazil strain primarily results in apoptosis, is more virulent, and results in excitotoxicity in a mouse model as compared to the Asian H/PF/2013 strain [50]. Similarly, these strains of ZIKV display a spectrum of effects on NSC activity and survival. Infection of NSCs by more pathogenic strains, such as the Brazilian Paraiba strain, leads to activation of the autophagy pathway, possibly to increase viral replication resulting in cell death [51]. Infection of NSCs with the African strains (MR766 and IB H 30656) are associated with more severe NSC cell death [52]. Interestingly, ZIKV-MR766 infection of NSCs caused apoptosis in a Musashi-1 dependent manner [53]. Musashi-1 is a neural RNA binding protein that is key for self-renewal of NSCs and neurogenesis [54]. The interaction between ZIKV-MR766 and a key NSC regulatory protein provides a mechanistic link between the apoptotic effects of the virus and resulting neuropathology. In contrast, the infection of NSCs by the H/PF/2013 strain of ZIKV leads to a mild cytopathic effect [41], while infection with PRVABC59 of ZIKV strain results in cycle arrest and reduced proliferation [55]. These results suggest that the severity of outcomes during viral infections in the brain could be dependent on the virus strain (Table 1) and how those strains impact NSCs.

In some CNS infections, the virus may not be fully cleared or controlled, but may persist in the CNS [56]. NSCs can maintain persistent infections in the surviving pool of cells, as has been observed for ZIKV and CVB3 [57,58]. HIV-1 also can persist in the CNS, potentially serving as a reservoir for the virus. Autopsy samples of HIV-1 patients with dementia revealed a reduction in NSC numbers compared to patients without dementia. Further in vitro studies suggested that the HIV gp120 protein reduced NSC proliferation via disruption of the extracellular signal-regulated kinase (ERK) pathway [59]. HSV-1 infection of adult NSCs results in reduced proliferation and neurogenesis without cell death and accumulation of amyloid- $\beta$  protein fragments, a biomarker of Alzheimer's disease [22,60]. While it is tempting to speculate about the potential role of viruses in neurodegenerative disease, these studies highlight that the consequences of viral infections in NSCs can be long-lasting and suggest that persistent viral infections may contribute to development of other neurological conditions.

### 3. Differentiation of NSCs

During brain development, NSCs differentiate in a temporal sequence with neurogenesis occurring first followed by gliogenesis [8,14,61–64]. In rodents, neurogenesis begins during early embryonic stages 10–11 (E10–E11) and continues till birth, although dendritic and axonal maturation continues postnatally [61,65]. Gliogenesis begins during late embryonic stages and peaks at birth [61,63,64]. In humans, both neurogenesis and gliogenesis occur majorly during gestation, but development continues even after birth [65]. The switch from neurogenesis to gliogenesis during development is tightly regulated by basic helix-loop-helix (bHLH) transcription factors and signaling pathways such as bone mor-

phogenetic proteins (BMPs), Notch, and the janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway [56,66]. In adults, the NSC pool becomes restricted to two neurogenic niches, the dentate gyrus (DG) of the hippocampus and the SVZ [14]. Specifically, NSCs in the DG give rise to glutamatergic excitatory dentate granule cells and contribute to spatial learning and memory [11,67–74]. While in the SVZ, the primary role of this NSC pool is to give rise to neuroblasts that migrate to the olfactory bulb (OB) via the rostral migratory stream (RMS) to support olfactory neurogenesis [71,75,76].

Aberrant differentiation of NSCs is associated with neurodevelopmental, neurodegenerative, and neuropsychiatric conditions. Increased neuronal density is observed in the prefrontal cortex of children with Autism spectrum disorder (ASD), suggesting increased neurogenesis [75–77]. In contrast, reduced neurogenesis, and a consequent decrease in number of mature neurons in both the hippocampus and SVZ, is seen in a mouse model of Parkinson's Disease (PD) with overexpression of human wild-type alpha synuclein [78,79]. Schizophrenia is also associated with reduced neurogenesis specifically in the hippocampus and prefrontal cortex [80]. These studies highlight that alterations in NSC differentiation may have functional consequences in development of the brain and of neurological disease.

Neurotropic viruses, including ZIKV, CMV, HSV, and borna disease virus (BDV) among others, can also alter NSC differentiation (Table 1) [81,82]. Viral infections can shift NSC fate toward the neuronal or glial lineage, sometimes at the expense of the other lineage or with no apparent impact on the other lineage. Viruses can also dampen differentiation broadly by inhibiting the formation of multiple neural cell types (Figure 1B). For example, HSV infection of NSCs decreases neuronal differentiation and shifts fate to the glial lineage [46,60], while BDV infection decreases neuronal differentiation with no impact on the glial lineage [2,83]. Commitment to the astroglial lineage is blocked by bovine viral diarrhea virus (BVDV) infection, whereas no changes were seen in the neuronal or oligodendroglial lineages [84]. JEV and CMV can inhibit both neuronal and glial differentiation, although Kosugi et al. showed that CMV inhibits neuronal lineage more profoundly [1,5,30,31,85]. As observed with NSC proliferation, the impact of ZIKV on differentiation is strain-dependent. The ZIKV Asian strain (H/PF/2013) and American strain (FB-GWUH-2016) are seen to lead to premature neuronal differentiation, while the ZIKV African (IBH 30656) and Brazilian (BR\_ZIKV\_AB\_ES) isolates were seen to inhibit neuronal differentiation. The ZIKV African isolate (IBH 30656) showed upregulation of a number of astrocytic genes, indicating that fate of NSCs might shift to the astroglial lineage [52,86–88]. These studies show that the impact of ZIKV infection on NSC differentiation is not monolithic and varies by strain and perhaps partly by the model system as well. Thus, viruses disrupt differentiation in multiple ways, including inhibition of a single lineage, shifting into alternative lineages, or broadly dampening differentiation into multiple cell types.

The exact mechanisms by which viruses impair NSC differentiation are not well understood. However, one could imagine that both viral proteins and cellular factors would contribute to changes in differentiation. Specific viral proteins from ZIKV and BDV have been identified that impair differentiation. The BDV phosphoprotein P, which is a part of the polymerase complex, is responsible for decreasing neuronal differentiation via downregulation of multiple neuronal genes [83]. Similarly, ZIKV non-structural (NS) proteins NS4A and NS4B, involved in viral replication and immune evasion, lead to reduction of both neuronal and astrocytic numbers [89–91]. Specifically, NS4A and 4B, whether expressed individually or together, were shown to inhibit the Akt-mTOR signaling pathway, which is important for neurogenesis and brain development [91–93]. The inhibition of the Akt-mTOR signaling also enhanced autophagy, which may support ZIKV replication as well as contribute to loss of the NSC pool [94–96]. These examples highlight that certain viral proteins are central to dysregulation of NSC differentiation.

The modulation of cellular proteins by the infection and subsequent immune response also contribute to aberrant differentiation. The JAK/STAT pathway is key to mediating the switch between neurogenesis and astroglialogenesis. During neurogenesis, the bHLH

transcription factors inhibit the expression of the JAK-STAT proteins in order to prevent premature formation of astrocytes. Downregulation of the bHLH factors leads to leukemia inhibitory factor (LIF)-mediated induction of the JAK/STAT-1/3 pathway, which triggers astrogliogenesis [66,97]. JEV infection of NSCs reduces JAK1 expression and STAT3 phosphorylation and increases STAT1 phosphorylation, thereby impairing astrocytic differentiation [1]. JEV also inhibited neuronal differentiation through downregulation of multiple neuronal genes (Ngn1, Ngn2, and NeuroD1) [1]. CMV similarly impairs neurogenesis, but through a distinct mechanism involving the peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ). PPAR $\gamma$  is a ligand dependent transcription factor that is highly expressed in the embryonic brain. In NSCs, PPAR $\gamma$  plays multiple roles in differentiation, including promotion of astrogliogenesis and inhibition of neurogenesis [85,94]. During CMV infection, PPAR $\gamma$  levels are elevated in the fetal brain. In vitro studies showed that PPAR $\gamma$  expression increased in CMV-infected NSCs and is associated with less neuronal differentiation [85,98]. Treatment of CMV-infected NSCs with a PPAR $\gamma$  inhibitor rescued abnormal differentiation, demonstrating the potential of identifying druggable targets for restoring NSC function.

The stage of NSC maturation is an important variable that determines susceptibility to infection and subsequent impacts on differentiation. Undifferentiated stem cells are often more permissible to viral infections and subsequent cell death, perhaps due to mounting a poor innate immune response as noted by the lower expression of Toll-like receptors, STAT1/2, and interferon-stimulated genes (ISGs) in undifferentiated NSCs versus more differentiated cells [1,99]. ZIKV infection of undifferentiated cells showed a greater cytopathic effect as compared to cells that have initiated astrocytic differentiation [55]. In differentiating NSCs, CMV decreased neuronal numbers only when infection occurred in the first 24 h after induction of differentiation; CMV infection at later time points did not impact neuronal differentiation [30]. These studies suggest that many viruses favor immature or undifferentiated NSCs, leading to greater viral infection but also more severe impacts on differentiation.

In addition to the virus, antiviral cytokines and chemokines can also disrupt NSC differentiation [15]. Chemokines orchestrate the movement of immune cells to the site of injury or infection, and chemokine receptors are often expressed on NSCs [95]. In a mouse model of congenital LCMV infection, persistent infection was associated with the expression of several chemokines (e.g., CCL2, CCL5, CXCL9, and CXCL10) in the neurogenic niches of the brain [37]. Persistent LCMV infection also reduced neuroblasts in the adult brain, which could be associated with the upregulation of these chemokines in the same regions [37]. Similarly, neonatal LCMV infection was associated with a decrease in adult neurogenesis in the DG, indicating that infections in the both the fetal and neonatal CNS could have long-lasting consequences [96]. Cytokines can also impact NSC differentiation. IL-1 $\beta$  impaired neurogenesis after WNV infection in adult mice and has been shown to have pro-gliogenic and anti-neurogenic effects on NSCs in vitro [100–102]. IFN $\gamma$  is a key antiviral cytokine that can modulate NSC activity [103,104]. In chronic HSV-1 infection, CD8 $^+$  T cells are the major source of IFN $\gamma$  in the brain. In vitro co-culture of CD8 $^+$  T cells and NSCs shifted differentiation towards the astroglial lineage in an IFN $\gamma$ -dependent manner [105]. Together, these findings suggest that viruses can disrupt NSC differentiation through expression of viral proteins, modulation of cellular factors, and the induction of cytokines and chemokines by the antiviral immune response.

#### 4. Conclusions

NSCs are critical for the extended development of the brain and for plasticity and repair in the mature CNS [106]. It is apparent that many neurotropic viruses are capable of disturbing NSC function, with profound consequences for the host in some instances. However, a number of outstanding questions remain regarding interactions between viruses and NSCs. Although changes in NSCs have been observed at the cellular level, how such changes contribute to neurological and psychiatric disorders is a complex question.

Damage from the acute infection and subsequent long-term alterations in the cellular organization of the brain are possible outcomes. Connections between neurotropic infections and neurodegenerative disease later in life, such as the relationship between HSV-1 infections and Alzheimer's disease, are currently being explored. Nevertheless, it is clear that the age of the host and the maturation of the NSCs are key variables in how viruses impact NSCs. TORCH pathogens [toxoplasmosis, other pathogens (e.g., syphilis, parvovirus), rubella, CMV, HSV], which are associated with congenital infections of the fetus or newborn, can cause catastrophic dysregulation and depletion of NSCs, contributing to a long-term loss of both neural progenitors and new neurons associated with microcephaly (see [107] for a comprehensive review). In a model of adult WNV infection, cytokine-mediated inhibition of hippocampal neurogenesis is associated with memory impairments, even though the number of NSCs remained stable [100].

As mechanisms of NSC dysfunction are being explored, it is important to consider the contributions of both the virus and the antiviral immune response. Due to overlap in signaling pathways between developmental and inflammatory cytokines (e.g., STAT signaling), cytokines produced in response to the virus can shift commitment of NSCs between neuronal and glial lineages. In vitro studies provide powerful tools for capturing interactions between NSCs and viruses or specific cytokines, which enhance our understanding of the factors that may influence cellular changes in vivo. However, it is ultimately necessary to assess the combination of the viral infection and signaling factors produced by immune and neural cells. In vivo studies with HSV-1 and WNV demonstrate the significance of specific cytokines (IFN $\gamma$  and IL-1 $\beta$ , respectively) that modulate NSC responses during infection [100,105], and provide a crucial model for understanding the complexity of viral pathogenesis in the brain.

**Table 1.** Effects of viral infections on NSC proliferation, survival, and differentiation.

<b>Virus</b>	<b>Model System/Cell Type</b>	<b>Effect on NSCs</b>	<b>Notes</b>
<b>HSV-1</b>	Infection of adult mice or hippocampal NSC cultures from neonatal mice	Inhibits NSC proliferation [60]	Accumulation of amyloid $\beta$ protein
	Human iPSC-derived NSC monolayer culture	Cell death [45]	
	Human iPSC-derived cerebral organoids	Moderate cell death compared to monolayer hNSC cultures [46]	Activation of pro-apoptotic genes
	Human iPSC-derived NSCs and cerebral organoids	Decreased expression of neuronal markers and increased astroglial markers [46]	
	Murine neonatal hippocampal NSCs	Inhibits neuronal and promotes astroglial differentiation [60]	
<b>HCMV</b>	Human fetal brain-derived NSCs	Inhibits NSC proliferation [34]	Disruption of Hes1 expression
	Human fetal NSCs	Induction of apoptosis of infected cells [30]	Unfolded protein response activation
	Human iPSC-derived NSCs	Induction of apoptosis [32]	
	Human fetal NSCs	Inhibits neuronal differentiation when infection occurs in first 24 h after induction of differentiation [30]	
	NSCs derived from human embryonic stem cells (ESCs)	Inhibits neuronal differentiation [85]	Via elevated PPAR $\gamma$ levels
<b>MCMV</b>	Murine embryonic cerebral stem cells	Reduction in NSC proliferation [31]	Inhibition of DNA replication
	Murine neonatal brain cell after intracerebral MCMV infection	Decreased neuronal numbers and decreased expression of immature neuronal markers [5]	
	Murine embryonic NSCs	Inhibits neuronal and astroglial differentiation but neuronal differentiation is more severely affected [31]	
<b>BDV</b>	Human fetal NSCs	Inhibits neuronal differentiation [2]	
	Human fetal NSCs expressing BDV phosphoprotein P or X protein	Inhibits neuronal differentiation [83]	Driven by BDV phosphoprotein P
<b>BVDV</b>	Bovine fetal NSCs	Inhibits astroglial differentiation [84]	
<b>EV71</b>	Murine brain-derived NSCs	Induction of apoptosis [38]	



Table 1. Cont.

Virus	Model System/Cell Type	Effect on NSCs	Notes
CVB3	CVB3-infected neonatal mice	Induction of apoptosis and inhibition of proliferation of SVZ NSCs [39,40]	
	JEV-infected neonatal mice	Loss of actively proliferating NSCs in the SVZ, impaired proliferation in vitro. [4]	
JEV	Human fetal NSC culture or NSCs isolated from brain of JEV-infected patients	Induction of apoptosis [42]	Increased expression of pro-apoptotic proteins and factors associated with ER stress. Increased cleavage of caspases-3, 7, 8, and 9.
	JEV-infected neonatal mice	Induction of apoptosis in the SVZ [108]	Reversed by atorvastatin treatment
	Murine neonatal SVZ NSCs	Inhibits neuronal and glial differentiation [1]	Downregulation of neuronal genes and decreased STAT3, JAK1, and increased STAT1 expression
LCMV	LCMV-infected neonatal mice	Increased cell death in the SVZ during adulthood [37]	
	Adult mouse brain harvested after neonatal LCMV infection	Decreased neuroblasts in the SVZ and SGZ [37]	Associated with chemokine expression
	Murine adult hippocampal and SVZ cells after congenital LCMV infection	Decrease in adult hippocampal neurogenesis [96]	
WNV	Human fibroblast iPSC-derived NSCs	Induction of apoptosis [41]	
USUV	Human fibroblast iPSC-derived NSCs	Induction of mild apoptosis of NSCs compared to WNV [41]	
HIV	Human NSCs treated with HIV gp120	Reduced proliferation and induction of quiescence.	Reduced Erk phosphorylation
	Hippocampal tissue from HIV patients	Reduced NSC numbers [59]	
	Adult murine hippocampal NSCs or adult mice treated with HIV gp120	Inhibition of NSC proliferation [33]	Cell cycle arrest in the G1 phase via MAPK pathway activation
	Fetal hNSCs treated with HIV tat	Increase in quiescent NSCs [36]	Increased nuclear localization of TRIM32 due to increased miR-155
	Adult brain tissue from HIV seropositive patients		

Table 1. Cont.

Virus	Model System/Cell Type	Effect on NSCs	Notes
ZIKV African strain (MR766)	Human iPSC-derived forebrain NSCs	Reduced cell proliferation [29]	DNA damage, activation of the DNA damage response (DDR), and cell cycle arrest in the S-phase
	Embryonic murine NSCs or human embryonic NSCs	Induction of apoptosis and autophagy [51]	Increases macroautophagy to promote viral replication and disrupts selective autophagy
	hNSC cell line	Induction of apoptosis [55]	Activation of DDR, increased phosphorylation of H2AX (cellular protein responsive to DDR), and increased PARP and cleaved caspase 3
African strain (IB H 30656)	Embryonic murine cortical NSCs	No effect on cell viability [52]	Cytopathic effect (alterations in NSC secretome)
	Embryonic murine NSCs	Downregulation of neuronal and oligodendroglial genes and upregulation of astroglial genes [52]	
American strain (PRVABC59)	Human iPSC-derived forebrain hNSCs infected with ZIKV	Reduction in proliferation [29]	DNA damage, activation of DDR, and cell cycle arrest in the S-phase
	Embryonic murine cortical NSCs	No effect on cell viability [52]	Mild DDR induction in comparison to MR766 strain and activation of p53
	hNSC cell line	Mild cytopathic effect (pyknotic nuclei) [55]	Poor innate immune activation in hNSCs
	Human fetal NSCs	Induction of apoptosis [57]	Persistent ZIKV infection
Brazilian strain (Paraiba)	Embryonic murine NSCs or human embryonic NSCs	Induction of apoptosis and autophagy in NSCs [51]	Increases macroautophagy to promote viral replication and disrupts selective autophagy
Brazilian strain (ZIKV-BR)	NSCs from human iPSCs from exfoliated deciduous teeth	Aberrant neuronal differentiation with downregulation of mature neuron markers and upregulation of immature neuron markers [86]	
Brazilian strain (BR_ZIKV_AB_ES)	Human iPSC-derived NSCs	Inhibits neuronal differentiation [88]	
French Polynesia strain (H/PF/2013)	Human iPSC-derived NSCs	No changes in cell viability [41]	Cleaved caspase-3
	Human iPSC-derived NSCs	Premature differentiation to neurons [87]	
American strain (FB-GWUH-2016)	Human iPSC-derived NSCs	Premature differentiation to neurons [87]	
ZIKV proteins (NS4A and NS4B)	Human fetal NSCs	Decreased neuronal and astrocytic numbers [91]	Inhibition of Akt-mTOR pathway

Currently, studies are underway to explore antiviral and anti-inflammatory drugs as tools to protect NSCs during viral infections. Atorvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, induces pro-survival signaling in NSCs through activation of the AKT and ERK-1/2 pathways [109]. In neonatal NSCs infected with JEV, atorvastatin protected the NSCs against apoptosis and preserved proliferation [108]. Anakinra, an antagonist of the IL-1 receptor, prevented learning deficits in a mouse model of WNV-induced cognitive dysfunction, where neurogenesis is impaired [100]. Together these studies highlight the importance of identifying specific pathways that are responsible for NSC dysfunction during viral infections in order to provide potential targets for therapeutic intervention.

**Author Contributions:** Y.S.K., M.N.C., A.C.M., L.A.O.; writing—original draft preparation; Y.S.K., M.N.C., A.C.M., L.A.O.; writing—review and editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the State of Pennsylvania CURE Grant to L.A.O.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Ariff, I.M.; Thounaojam, M.C.; Das, S.; Basu, A. Japanese Encephalitis Virus Infection Alters Both Neuronal and Astrocytic Differentiation of Neural Stem/Progenitor Cells. *J. Neuroimmune Pharmacol.* **2013**, *8*, 664–676. [[CrossRef](#)]
2. Brnic, D.; Stevanovic, V.; Cochet, M.; Agier, C.; Richardson, J.; Montero-Menei, C.N.; Milhavet, O.; Eloit, M.; Couplier, M. Borna Disease Virus Infects Human Neural Progenitor Cells and Impairs Neurogenesis. *J. Virol.* **2012**, *86*, 2512–2522. [[CrossRef](#)] [[PubMed](#)]
3. Bonthius, D.J. Lymphocytic Choriomeningitis Virus: An Underrecognized Cause of Neurologic Disease in the Fetus, Child, and Adult. *Semin. Pediatric Neurol.* **2012**, *19*, 89–95. [[CrossRef](#)] [[PubMed](#)]
4. Das, S.; Basu, A. Japanese encephalitis virus infects neural progenitor cells and decreases their proliferation. *J. Neurochem.* **2008**, *106*, 1624–1636. [[CrossRef](#)] [[PubMed](#)]
5. Mutnal, M.B.; Cheeran, M.C.-J.; Hu, S.; Lokensgard, J.R. Murine Cytomegalovirus Infection of Neural Stem Cells Alters Neurogenesis in the Developing Brain. *PLoS ONE* **2011**, *6*, e16211. [[CrossRef](#)]
6. Puccini, J.M.; Ruller, C.M.; Robinson, S.M.; Knopp, K.A.; Buchmeier, M.J.; Doran, K.S.; Feuer, R. Distinct neural stem cell tropism, early immune activation, and choroid plexus pathology following coxsackievirus infection in the neonatal central nervous system. *Lab. Investig.* **2014**, *94*, 161–181. [[CrossRef](#)]
7. Tang, H.; Hammack, C.; Ogden, S.C.; Wen, Z.; Qian, X.; Li, Y.; Yao, B.; Shin, J.; Zhang, F.; Lee, E.M.; et al. Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. *Cell Stem Cell* **2016**, *18*, 587–590. [[CrossRef](#)] [[PubMed](#)]
8. Zhao, X.; Moore, D.L. Neural stem cells: Developmental mechanisms and disease modeling. *Cell Tissue Res.* **2018**, *371*, 1–6. [[CrossRef](#)] [[PubMed](#)]
9. Homem, C.; Repic, M.; Knoblich, J.A. Proliferation control in neural stem and progenitor cells. *Nat. Rev. Neurosci.* **2015**, *16*, 647–659. [[CrossRef](#)]
10. Liszewska, E.; Jaworski, J. Neural Stem Cell Dysfunction in Human Brain Disorders. *Chem. Biol. Pteridines Foliates* **2018**, *66*, 283–305. [[CrossRef](#)]
11. Kempermann, G.; Song, H.; Gage, F.H. Neurogenesis in the Adult Hippocampus. *Cold Spring Harb. Perspect. Biol.* **2015**, *7*, a018812. [[CrossRef](#)]
12. Gonzalez-Perez, O. Neural stem cells in the adult human brain. *Biol. Biomed. Rep.* **2012**, *2*, 59–69. [[PubMed](#)]
13. Berdugo-Vega, G.; Arias-Gil, G.; López-Fernández, A.; Artegiani, B.; Wasielewska, J.M.; Lee, C.-C.; Lippert, M.T.; Kempermann, G.; Takagaki, K.; Calegari, F. Increasing neurogenesis refines hippocampal activity rejuvenating navigational learning strategies and contextual memory throughout life. *Nat. Commun.* **2020**, *11*, 135. [[CrossRef](#)] [[PubMed](#)]
14. Temple, S. The development of neural stem cells. *Nat. Cell Biol.* **2001**, *414*, 112–117. [[CrossRef](#)] [[PubMed](#)]
15. Chandwani, M.N.; Creisher, P.S.; O'Donnell, L.A. Understanding the Role of Antiviral Cytokines and Chemokines on Neural Stem/Progenitor Cell Activity and Survival. *Viral Immunol.* **2019**, *32*, 15–24. [[CrossRef](#)] [[PubMed](#)]
16. Bauer, S. Cytokine Control of Adult Neural Stem Cells. *Ann. N.Y. Acad. Sci.* **2009**, *1153*, 48–56. [[CrossRef](#)] [[PubMed](#)]
17. Carpentier, P.A.; Palmer, T.D. Immune Influence on Adult Neural Stem Cell Regulation and Function. *Neuron* **2009**, *64*, 79–92. [[CrossRef](#)] [[PubMed](#)]

18. Latchney, S.E.; Eisch, A.J. Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: Regeneration and beyond. *Eur. J. Neurodegener. Dis.* **2012**, *1*, 335–351.
19. Yau, S.-Y.; Li, A.; So, K.-F. Involvement of Adult Hippocampal Neurogenesis in Learning and Forgetting. *Neural Plast.* **2015**, *2015*, 717958. [[CrossRef](#)]
20. Barton, L.L.; Peters, C.J.; Ksiazek, T.G.; Barton, L.L.; Peters, C.J.; Ksiazek, T.G. Lymphocytic Choriomeningitis Virus: An Unrecognized Teratogenic Pathogen. *Emerg. Infect. Dis.* **1995**, *1*, 152–153. [[CrossRef](#)]
21. Dutta, K.; Rangarajan, P.N.; Vrati, S.; Basu, A. Japanese encephalitis: Pathogenesis, prophylactics and therapeutics. *Curr. Sci.* **2010**, *98*, 326–334.
22. Maccoci, M.E.; Napoletani, G.; Protto, V.; Kolesova, O.; Piacentini, R.; Puma, D.D.L.; Lomonte, P.; Grassi, C.; Palamara, A.T.; De Chiara, G. Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection. *Trends Microbiol.* **2020**, *28*, 808–820. [[CrossRef](#)]
23. Calvet, G.; Aguiar, R.S.; O Melo, A.S.; Sampaio, S.A.; de Filippis, I.; Fabri, A.; Araujo, E.S.M.; de Sequeira, P.C.; de Mendonça, M.C.L.; de Oliveira, L.; et al. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: A case study. *Lancet Infect. Dis.* **2016**, *16*, 653–660. [[CrossRef](#)]
24. Brasil, P.; Pereira, J.P., Jr.; Moreira, M.E.; Ribeiro Nogueira, R.M.; Damasceno, L.; Wakimoto, M.; Rabello, R.S.; Valderramos, S.G.; Halai, U.-A.; Salles, T.S.; et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. *N. Engl. J. Med.* **2016**, *375*, 2321–2334. [[CrossRef](#)]
25. Leal, M.D.C.; Muniz, L.F.; Neto, S.D.S.C.; Van Der Linden, V.; Ramos, R.C.F. Sensorineural hearing loss in a case of congenital Zika virus. *Braz. J. Otorhinolaryngol.* **2020**, *86*, 513–515. [[CrossRef](#)]
26. Khacho, M.; Harris, R.; Slack, R.S. Mitochondria as central regulators of neural stem cell fate and cognitive function. *Nat. Rev. Neurosci.* **2019**, *20*, 34–48. [[CrossRef](#)]
27. Figueiredo, C.P.; Barros-Aragão, F.G.Q.; Neris, R.L.S.; Frost, P.S.; Soares, C.; Souza, I.N.O.; Zeidler, J.D.; Zamberlan, D.C.; De Sousa, V.L.; Souza, A.S.; et al. Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice. *Nat. Commun.* **2019**, *10*, 3890. [[CrossRef](#)]
28. Gabriel, E.; Ramani, A.; Altinisik, N.; Gopalakrishnan, J. Human Brain Organoids to Decode Mechanisms of Microcephaly. *Front. Cell. Neurosci.* **2020**, *14*, 115. [[CrossRef](#)] [[PubMed](#)]
29. Hammack, C.; Ogden, S.C.; Madden, J.C.; Medina, A.; Xu, C.; Phillips, E.; Son, Y.; Cone, A.; Giovinazzi, S.; Didier, R.A.; et al. Zika Virus Infection Induces DNA Damage Response in Human Neural Progenitors That Enhances Viral Replication. *J. Virol.* **2019**, *93*, e00638-19. [[CrossRef](#)] [[PubMed](#)]
30. Odeberg, J.; Wolmer, N.; Falci, S.; Westgren, M.; Seiger, A.; Söderberg-Nauclér, C. Human Cytomegalovirus Inhibits Neuronal Differentiation and Induces Apoptosis in Human Neural Precursor Cells. *J. Virol.* **2006**, *80*, 8929–8939. [[CrossRef](#)] [[PubMed](#)]
31. Kosugi, I.; Shinmura, Y.; Kawasaki, H.; Arai, Y.; Li, R.-Y.; Baba, S.; Tsutsui, Y. Cytomegalovirus Infection of the Central Nervous System Stem Cells from Mouse Embryo: A Model for Developmental Brain Disorders Induced by Cytomegalovirus. *Lab. Invest.* **2000**, *80*, 1373–1383. [[CrossRef](#)]
32. Nakamura, H.; Liao, H.; Minami, K.; Toyoda, M.; Akutsu, H.; Miyagawa, Y.; Okita, H.; Kiyokawa, N.; Umezawa, A.; Imadome, K.-I.; et al. Human cytomegalovirus induces apoptosis in neural stem/progenitor cells derived from induced pluripotent stem cells by generating mitochondrial dysfunction and endoplasmic reticulum stress. *Herpesviridae* **2013**, *4*, 2. [[CrossRef](#)]
33. Okamoto, S.-I.; Kang, Y.-J.; Brechtel, C.W.; Siviglia, E.; Russo, R.; Clemente, A.; Harrop, A.; McKercher, S.; Kaul, M.; Lipton, S.A. HIV/gp120 Decreases Adult Neural Progenitor Cell Proliferation via Checkpoint Kinase-Mediated Cell-Cycle Withdrawal and G1 Arrest. *Cell Stem Cell* **2007**, *1*, 230–236. [[CrossRef](#)] [[PubMed](#)]
34. Liu, X.-J.; Jiang, X.; Huang, S.-N.; Sun, J.-Y.; Zhao, F.; Zeng, W.-B.; Luo, M.-H. Human cytomegalovirus infection dysregulates neural progenitor cell fate by disrupting Hes1 rhythm and down-regulating its expression. *Virol. Sin.* **2017**, *32*, 188–198. [[CrossRef](#)] [[PubMed](#)]
35. Harris, L.; Guillemot, F. HES1, two programs: Promoting the quiescence and proliferation of adult neural stem cells. *Genes Dev.* **2019**, *33*, 479–481. [[CrossRef](#)] [[PubMed](#)]
36. Fatima, M.; Kumari, R.; Schwamborn, J.C.; Mahadevan, A.; Shankar, S.K.; Raja, R.; Seth, P. Tripartite containing motif 32 modulates proliferation of human neural precursor cells in HIV-1 neurodegeneration. *Cell Death Differ.* **2016**, *23*, 776–786. [[CrossRef](#)]
37. Sun, T.; Vasek, M.; Klein, R.S. Congenitally Acquired Persistent Lymphocytic Choriomeningitis Viral Infection Reduces Neuronal Progenitor Pools in the Adult Hippocampus and Subventricular Zone. *PLoS ONE* **2014**, *9*, e96442. [[CrossRef](#)]
38. Huang, H.-I.; Lin, J.-Y.; Chen, H.-H.; Yeh, S.-B.; Kuo, R.-L.; Weng, K.-F.; Shih, S.-R. Enterovirus 71 infects brain-derived neural progenitor cells. *Virology* **2014**, *468-470*, 592–600. [[CrossRef](#)] [[PubMed](#)]
39. Feuer, R.; Pagarigan, R.R.; Harkins, S.; Liu, F.; Hunziker, I.P.; Whitton, J.L. Coxsackievirus Targets Proliferating Neuronal Progenitor Cells in the Neonatal CNS. *J. Neurosci.* **2005**, *25*, 2434–2444. [[CrossRef](#)]
40. Ruller, C.M.; Tabor-Godwin, J.M.; Van Deren, D.A.; Robinson, S.M.; Maciejewski, S.; Gluhm, S.; Gilbert, P.E.; An, N.; Gude, N.A.; Sussman, M.A.; et al. Neural Stem Cell Depletion and CNS Developmental Defects After Enteroviral Infection. *Am. J. Pathol.* **2012**, *180*, 1107–1120. [[CrossRef](#)]
41. Riccetti, S.; Sinigaglia, A.; Desole, G.; Nowotny, N.; Trevisan, M.; Barzon, L. Modelling West Nile Virus and Usutu Virus Pathogenicity in Human Neural Stem Cells. *Viruses* **2020**, *12*, 882. [[CrossRef](#)] [[PubMed](#)]

42. Mukherjee, S.; Singh, N.; Sengupta, N.; Fatima, M.; Seth, P.; Mahadevan, A.; Shankar, S.K.; Bhattacharyya, A.; Basu, A. Japanese encephalitis virus induces human neural stem/progenitor cell death by elevating GRP78, PHB and hnRNPC through ER stress. *Cell Death Dis.* **2017**, *8*, e2556. [[CrossRef](#)]
43. Choi, J.-A.; Song, C.-H. Insights into the role of endoplasmic reticulum stress in infectious diseases. *Front. Immunol.* **2019**, *10*, 3147. [[CrossRef](#)]
44. Jheng, J.R.; Ho, J.Y.; Horng, J.T. ER stress, autophagy, and RNA viruses. *Front. Microbiol.* **2014**, *5*, 388. [[CrossRef](#)]
45. Zheng, W.; Klammer, A.M.; Naciri, J.N.; Yeung, J.; Demers, M.; Milosevich, J.; Kinchington, P.R.; Bloom, D.C.; Nimgaonkar, V.L.; D'Aiuto, L. Patterns of Herpes Simplex Virus 1 Infection in Neural Progenitor Cells. *J. Virol.* **2020**, *94*, e00994-20. [[CrossRef](#)]
46. Qiao, H.; Guo, M.; Shang, J.; Zhao, W.; Wang, Z.; Liu, N.; Li, B.; Zhou, Y.; Wu, Y.; Chen, P. Herpes simplex virus type 1 infection leads to neurodevelopmental disorder-associated neuropathological changes. *PLOS Pathog.* **2020**, *16*, e1008899. [[CrossRef](#)] [[PubMed](#)]
47. Kawai, Y.; Nakayama, E.; Takahashi, K.; Taniguchi, S.; Shibasaki, K.-I.; Kato, F.; Maeki, T.; Suzuki, T.; Tajima, S.; Saijo, M.; et al. Increased growth ability and pathogenicity of American- and Pacific-subtype Zika virus (ZIKV) strains compared with a Southeast Asian-subtype ZIKV strain. *PLoS Negl. Trop. Dis.* **2019**, *13*, e0007387. [[CrossRef](#)]
48. Ramos da Silva, S.; Ramos da Silva, S.; Cheng, F.; Huang, I.C.; Jung, J.U.; Gao, S.J. Efficiencies and kinetics of infection in different cell types/lines by African and Asian strains of Zika virus. *J. Med. Virol.* **2019**, *91*, 179–189. [[CrossRef](#)]
49. Simonin, Y.; Van Riel, D.; Van de Perre, P.; Rockx, B.; Salinas, S. Differential virulence between Asian and African lineages of Zika virus. *PLoS Negl. Trop. Dis.* **2017**, *11*, e0005821. [[CrossRef](#)] [[PubMed](#)]
50. Noguchi, K.K.; Swiney, B.S.; Williams, S.L.; Huffman, J.N.; Lucas, K.; Wang, S.H.; Kapral, K.M.; Li, A.; Dikranian, K.T. Zika Virus Infection in the Developing Mouse Produces Dramatically Different Neuropathology Dependent on Viral Strain. *J. Neurosci.* **2020**, *40*, 1145–1161. [[CrossRef](#)] [[PubMed](#)]
51. Tiwari, S.K.; Dang, J.W.; Lin, N.; Qin, Y.; Wang, S.; Rana, T.M. Zika virus depletes neural stem cells and evades selective autophagy by suppressing the Fanconi anemia protein FANCC. *EMBO Rep.* **2020**, *21*, e49183. [[CrossRef](#)]
52. Lossia, O.V.; Conway, M.J.; Tree, M.O.; Williams, R.J.; Goldthorpe, S.C.; Srinageshwar, B.; Dunbar, G.L.; Rossignol, J. Zika virus induces astrocyte differentiation in neural stem cells. *J. NeuroVirology* **2018**, *24*, 52–61. [[CrossRef](#)] [[PubMed](#)]
53. Chavali, P.L.; Stojic, L.; Meredith, L.W.; Joseph, N.; Nahorski, M.S.; Sanford, T.J.; Sweeney, T.R.; Krishna, B.A.; Hosmillo, M.; Firth, A.E.; et al. Neurodevelopmental protein Musashi-1 interacts with the Zika genome and promotes viral replication. *Science* **2017**, *357*, 83–88. [[CrossRef](#)] [[PubMed](#)]
54. Okano, H.; Kawahara, H.; Toriya, M.; Nakao, K.; Shibata, S.; Imai, T. Function of RNA-binding protein Musashi-1 in stem cells. *Exp. Cell Res.* **2005**, *306*, 349–356. [[CrossRef](#)] [[PubMed](#)]
55. Devhare, P.; Meyer, K.; Steele, R.; Ray, R.B.; Ray, R. Zika virus infection dysregulates human neural stem cell growth and inhibits differentiation into neuroprogenitor cells. *Cell Death Dis.* **2017**, *8*, e3106. [[CrossRef](#)] [[PubMed](#)]
56. Miller, F.D.; Gauthier, A.S. Timing Is Everything: Making Neurons versus Glia in the Developing Cortex. *Neuron* **2007**, *54*, 357–369. [[CrossRef](#)]
57. Hanners, N.W.; Eitson, J.L.; Usui, N.; Richardson, R.B.; Wexler, E.M.; Konopka, G.; Schoggins, J.W. Western Zika Virus in Human Fetal Neural Progenitors Persists Long Term with Partial Cytopathic and Limited Immunogenic Effects. *Cell Rep.* **2016**, *15*, 2315–2322. [[CrossRef](#)] [[PubMed](#)]
58. Tsueng, G.; Tabor-Godwin, J.M.; Gopal, A.; Ruller, C.M.; Deline, S.; An, N.; Frausto, R.F.; Milner, R.; Crocker, S.J.; Whitton, J.L.; et al. Cocksackievirus Preferentially Replicates and Induces Cytopathic Effects in Undifferentiated Neural Progenitor Cells. *J. Virol.* **2011**, *85*, 5718–5732. [[CrossRef](#)]
59. Krathwohl, M.D.; Kaiser, J.L. HIV-1 Promotes Quiescence in Human Neural Progenitor Cells. *J. Infect. Dis.* **2004**, *190*, 216–226. [[CrossRef](#)]
60. Li Puma, D.D.; Piacentini, R.; Leone, L.; Gironi, K.; Maccocci, M.E.; De Chiara, G.; Palamara, A.T.; Grassi, C. Herpes Simplex Virus Type-1 Infection Impairs Adult Hippocampal Neurogenesis via Amyloid-beta Protein Accumulation. *Stem Cells* **2019**, *37*, 1467–1480. [[CrossRef](#)]
61. Bond, A.M.; Berg, D.A.; Lee, S.; Garcia-Epelboim, A.S.; Adusumilli, V.S.; Ming, G.-L.; Song, H. Differential Timing and Coordination of Neurogenesis and Astrogenesis in Developing Mouse Hippocampal Subregions. *Brain Sci.* **2020**, *10*, 909. [[CrossRef](#)]
62. Okano, H.; Temple, S. Cell types to order: Temporal specification of CNS stem cells. *Curr. Opin. Neurobiol.* **2009**, *19*, 112–119. [[CrossRef](#)] [[PubMed](#)]
63. Farhy-Tselnicker, I.; Allen, N.J. Astrocytes, neurons, synapses: A tripartite view on cortical circuit development. *Neural Dev.* **2018**, *13*, 1–12. [[CrossRef](#)] [[PubMed](#)]
64. Bergles, D.E.; Richardson, W.D. Oligodendrocyte Development and Plasticity. *Cold Spring Harb. Perspect. Biol.* **2016**, *8*, a020453. [[CrossRef](#)]
65. Semple, B.D.; Blomgren, K.; Gimlin, K.; Ferriero, D.M.; Noble-Haeusslein, L.J. Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. *Prog. Neurobiol.* **2013**, *106–107*, 1–16. [[CrossRef](#)]
66. He, F.; Ge, W.; Martinowich, K.; Becker-Catania, S.; Coskun, V.; Zhu, W.; Wu, H.; Castro, D.; Guillemot, F.; Fan, G.; et al. A positive autoregulatory loop of Jak-STAT signaling controls the onset of astroglialogenesis. *Nat. Neurosci.* **2005**, *8*, 616–625. [[CrossRef](#)]

67. Alonso, M.; Viollet, C.; Gabellec, M.-M.; Meas-Yedid, V.; Olivo-Marin, J.-C.; Lledo, P.-M. Olfactory Discrimination Learning Increases the Survival of Adult-Born Neurons in the Olfactory Bulb. *J. Neurosci.* **2006**, *26*, 10508–10513. [[CrossRef](#)]
68. Eriksson, P.S.; Perfilieva, E.; Bjork-Eriksson, T.; Alborn, A.-M.; Nordborg, C.; Peterson, D.A.; Gage, F.H. Neurogenesis in the adult human hippocampus. *Nat. Med.* **1998**, *4*, 1313–1317. [[CrossRef](#)] [[PubMed](#)]
69. Spalding, K.; Bergmann, O.; Alkass, K.; Bernard, S.; Salehpour, M.; Huttner, H.B.; Boström, E.; Westerlund, I.; Vial, C.; Buchholz, B.; et al. Dynamics of Hippocampal Neurogenesis in Adult Humans. *Cell* **2013**, *153*, 1219–1227. [[CrossRef](#)]
70. Dupret, D.; Revest, J.-M.; Koehl, M.; Ichas, F.; De Giorgi, F.; Costet, P.; Abrous, D.N.; Piazza, P.V. Spatial Relational Memory Requires Hippocampal Adult Neurogenesis. *PLoS ONE* **2008**, *3*, e1959. [[CrossRef](#)]
71. Ma, D.K.; Bonaguidi, M.A.; Ming, G.-L.; Song, H. Adult neural stem cells in the mammalian central nervous system. *Cell Res.* **2009**, *19*, 672–682. [[CrossRef](#)] [[PubMed](#)]
72. Gonçalves, J.T.; Schafer, S.T.; Gage, F.H. Adult Neurogenesis in the Hippocampus: From Stem Cells to Behavior. *Cell* **2016**, *167*, 897–914. [[CrossRef](#)] [[PubMed](#)]
73. Berg, D.A.; Belnoue, L.; Song, H.; Simon, A. Neurotransmitter-mediated control of neurogenesis in the adult vertebrate brain. *Development* **2013**, *140*, 2548–2561. [[CrossRef](#)] [[PubMed](#)]
74. Takei, Y. Age-dependent decline in neurogenesis of the hippocampus and extracellular nucleotides. *Hum. Cell* **2019**, *32*, 88–94. [[CrossRef](#)]
75. Courchesne, E.; Mouton, P.R.; Calhoun, M.E.; Semendeferi, K.; Ahrens-Barbeau, C.; Hallet, M.J.; Barnes, C.C.; Pierce, K. Neuron Number and Size in Prefrontal Cortex of Children with Autism. *JAMA* **2011**, *306*, 2001–2010. [[CrossRef](#)] [[PubMed](#)]
76. Casanova, E.L.; Casanova, M.F. Genetics studies indicate that neural induction and early neuronal maturation are disturbed in autism. *Front. Cell. Neurosci.* **2014**, *8*, 397. [[CrossRef](#)]
77. Pang, Y.; Fan, L.-W. Dysregulation of neurogenesis by neuroinflammation: Key differences in neurodevelopmental and neurological disorders. *Neural Regen. Res.* **2017**, *12*, 366–371. [[CrossRef](#)] [[PubMed](#)]
78. Winner, B.; Lie, D.C.; Rockenstein, E.; Aigner, R.; Aigner, L.; Masliah, E.; Kuhn, H.G.; Winkler, J. Human Wild-Type  $\alpha$ -Synuclein Impairs Neurogenesis. *J. Neuropathol. Exp. Neurol.* **2004**, *63*, 1155–1166. [[CrossRef](#)]
79. Desplats, P.; Spencer, B.; Crews, L.; Pathel, P.; Morvinski-Friedmann, D.; Kosberg, K.; Roberts, S.; Patrick, C.; Winner, B.; Winkler, J.; et al.  $\alpha$ -Synuclein Induces Alterations in Adult Neurogenesis in Parkinson Disease Models via p53-mediated Repression of Notch1. *J. Biol. Chem.* **2012**, *287*, 31691–31702. [[CrossRef](#)]
80. Iannitelli, A.; Quartini, A.; Tirassa, P.; Bersani, G. Schizophrenia and neurogenesis: A stem cell approach. *Neurosci. Biobehav. Rev.* **2017**, *80*, 414–442. [[CrossRef](#)]
81. Dahm, T.; Rudolph, H.; Schwerk, C.; Schroten, H.; Tenenbaum, T. Neuroinvasion and Inflammation in Viral Central Nervous System Infections. *Mediat. Inflamm.* **2016**, *2016*, 1–16. [[CrossRef](#)]
82. Das, S.; Basu, A. Viral infection and neural stem/progenitor cell's fate: Implications in brain development and neurological disorders. *Neurochem. Int.* **2011**, *59*, 357–366. [[CrossRef](#)]
83. Scordel, C.; Huttin, A.; Cochet-Bernoin, M.; Szelechowski, M.; Poulet, A.; Richardson, J.; Benchoua, A.; Gonzalez-Dunia, D.; Eloit, M.; Couplier, M. Borna Disease Virus Phosphoprotein Impairs the Developmental Program Controlling Neurogenesis and Reduces Human GABAergic Neurogenesis. *PLoS Pathog.* **2015**, *11*, e1004859. [[CrossRef](#)] [[PubMed](#)]
84. Matsuda, K.; Kobayashi, S.; Kameyama, K.-I.; Sato, M.; Koiwa, M.; Sakoda, Y.; Taniyama, H. Non-cytopathic bovine viral diarrhea virus infection inhibits differentiation of bovine neural stem/progenitor cells into astrocytes in vitro. *J. Vet. Med. Sci.* **2010**, *72*, 903–907. [[CrossRef](#)] [[PubMed](#)]
85. Rolland, M.; Li, X.; Sellier, Y.; Martin, H.; Perez-Berezo, T.; Rauwel, B.; Benchoua, A.; Bessières, B.; Aziza, J.; Cenac, N.; et al. PPAR $\gamma$  Is Activated during Congenital Cytomegalovirus Infection and Inhibits Neuronogenesis from Human Neural Stem Cells. *PLoS Pathog.* **2016**, *12*, e1005547. [[CrossRef](#)] [[PubMed](#)]
86. Rosa-Fernandes, L.; Cugola, F.R.; Russo, F.B.; Kawahara, R.; Freire, C.C.D.M.; Leite, P.E.C.; Stern, A.C.B.; Angeli, C.B.; De Oliveira, D.B.L.; Melo, S.R.; et al. Zika Virus Impairs Neurogenesis and Synaptogenesis Pathways in Human Neural Stem Cells and Neurons. *Front. Cell. Neurosci.* **2019**, *13*, 64. [[CrossRef](#)]
87. Gabriel, E.; Ramani, A.; Karow, U.; Gottardo, M.; Natarajan, K.; Gooi, L.M.; Goranci-Buzhala, G.; Krut, O.; Peters, F.; Nikolić, M.; et al. Recent Zika Virus Isolates Induce Premature Differentiation of Neural Progenitors in Human Brain Organoids. *Cell Stem Cell* **2017**, *20*, 397–406.e5. [[CrossRef](#)] [[PubMed](#)]
88. Garcez, P.P.; Nascimento, J.M.; De Vasconcelos, J.M.; Da Costa, R.M.; DelVecchio, R.; Trindade, P.; Loiola, E.C.; Higa, L.M.; Cassoli, J.S.; Vitória, G.; et al. Zika virus disrupts molecular fingerprinting of human neurospheres. *Sci. Rep.* **2017**, *7*, srep40780. [[CrossRef](#)]
89. Ma, J.; Ketkar, H.; Geng, T.; Lo, E.; Wang, L.; Xi, J.; Sun, Q.; Zhu, Z.; Cui, Y.; Yang, L.; et al. Zika Virus Non-structural Protein 4A Blocks the RLR-MAVS Signaling. *Front. Microbiol.* **2018**, *9*, 1350. [[CrossRef](#)]
90. Ngono, A.E.; Shresta, S. Immune Response to Dengue and Zika. *Annu. Rev. Immunol.* **2018**, *36*, 279–308. [[CrossRef](#)]
91. Liang, Q.; Luo, Z.; Zeng, J.; Chen, W.; Foo, S.S.; Lee, S.A.; Ge, J.; Su, W.; Goldman, S.A.; Zlokovic, B.V.; et al. Zika Virus NS4A and NS4B Proteins Deregulate Akt-mTOR Signaling in Human Fetal Neural Stem Cells to Inhibit Neurogenesis and Induce Autophagy. *Cell Stem Cell* **2016**, *19*, 663–671. [[CrossRef](#)] [[PubMed](#)]
92. Lee, D.Y. Roles of mTOR Signaling in Brain Development. *Exp. Neurobiol.* **2015**, *24*, 177–185. [[CrossRef](#)] [[PubMed](#)]

93. Wahane, S.; Hellbach, N.; Prentzell, M.T.; Weise, S.C.; Vezzali, R.; Kreutz, C.; Timmer, J.; Krieglstein, K.; Thedieck, K.; Vogel, T. PI3K-p110-alpha-subtype signalling mediates survival, proliferation and neurogenesis of cortical progenitor cells via activation of mTORC2. *J. Neurochem.* **2014**, *130*, 255–267. [[CrossRef](#)]
94. Stergiopoulos, A.; Politis, P.K. The role of nuclear receptors in controlling the fine balance between proliferation and differentiation of neural stem cells. *Arch. Biochem. Biophys.* **2013**, *534*, 27–37. [[CrossRef](#)]
95. Hughes, C.E.; Nibbs, R.J.B. A guide to chemokines and their receptors. *FEBS J.* **2018**, *285*, 2944–2971. [[CrossRef](#)]
96. Sharma, A.; Valadi, N.; Miller, A.H.; Pearce, B.D. Neonatal Viral Infection Decreases Neuronal Progenitors and Impairs Adult Neurogenesis in the Hippocampus. *Neurobiol. Dis.* **2002**, *11*, 246–256. [[CrossRef](#)]
97. Deverman, B.E.; Patterson, P.H. Cytokines and CNS Development. *Neuron* **2009**, *64*, 61–78. [[CrossRef](#)] [[PubMed](#)]
98. Chavanas, S. Peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) activation: A key determinant of neuropathogeny during congenital infection by cytomegalovirus. *Neurogenesis* **2016**, *3*, e1231654. [[CrossRef](#)]
99. Ferraris, P.; Cochet, M.; Hamel, R.; Gladwyn-Ng, I.; Alfano, C.; Diop, F.; Garcia, D.; Talignani, L.; Montero-Menei, C.N.; Nougairède, A.; et al. Zika virus differentially infects human neural progenitor cells according to their state of differentiation and dysregulates neurogenesis through the Notch pathway. *Emerg. Microbes Infect.* **2019**, *8*, 1003–1016. [[CrossRef](#)]
100. Garber, C.; Vasek, M.; Vollmer, L.; Sun, T.; Jiang, X.; Klein, R.S. Astrocytes decrease adult neurogenesis during virus-induced memory dysfunction via IL-1. *Nat. Immunol.* **2018**, *19*, 151–161. [[CrossRef](#)]
101. Green, H.F.; Treacy, E.; Keohane, A.; Sullivan, A.; O’Keeffe, G.W.; Nolan, Y.M. A role for interleukin-1 $\beta$  in determining the lineage fate of embryonic rat hippocampal neural precursor cells. *Mol. Cell. Neurosci.* **2012**, *49*, 311–321. [[CrossRef](#)]
102. Wang, X.; Fu, S.; Wang, Y.; Yu, P.; Hu, J.; Gu, W.; Xu, X.-M.; Lu, P. Interleukin-1beta mediates proliferation and differentiation of multipotent neural precursor cells through the activation of SAPK/JNK pathway. *Mol. Cell Neurosci.* **2007**, *36*, 343–354. [[CrossRef](#)]
103. Walter, J.; Honsek, S.D.; Illes, S.; Wellen, J.M.; Hartung, H.-P.; Rose, C.R.; Dihné, M. A new role for interferon gamma in neural stem/precursor cell dysregulation. *Mol. Neurodegener.* **2011**, *6*, 18. [[CrossRef](#)] [[PubMed](#)]
104. Kulkarni, A.; Scully, T.J.; O’Donnell, L.A. The antiviral cytokine interferon-gamma restricts neural stem/progenitor cell proliferation through activation of STAT1 and modulation of retinoblastoma protein phosphorylation. *J. Neurosci. Res.* **2016**, *95*, 1582–1601. [[CrossRef](#)] [[PubMed](#)]
105. Hu, S.; Rotschafer, J.H.; Lokensgard, J.R.; Cheeran, M.C.-J. Activated CD8+ T Lymphocytes Inhibit Neural Stem/Progenitor Cell Proliferation: Role of Interferon-Gamma. *PLoS ONE* **2014**, *9*, e105219. [[CrossRef](#)]
106. Silbereis, J.C.; Pochareddy, S.; Zhu, Y.; Li, M.; Sestan, N. The Cellular and Molecular Landscapes of the Developing Human Central Nervous System. *Neuron* **2016**, *89*, 248–268. [[CrossRef](#)] [[PubMed](#)]
107. Baggiani, M.; Dell’Anno, M.T.; Pistello, M.; Conti, L.; Onorati, M. Human Neural Stem Cell Systems to Explore Pathogen-Related Neurodevelopmental and Neurodegenerative Disorders. *Cells* **2020**, *9*, 1893. [[CrossRef](#)] [[PubMed](#)]
108. Wani, M.A.; Mukherjee, S.; Mallick, S.; Akbar, I.; Basu, A. Atorvastatin ameliorates viral burden and neural stem/progenitor cell (NSPC) death in an experimental model of Japanese encephalitis. *J. Biosci.* **2020**, *45*, 1–17. [[CrossRef](#)]
109. Choi, N.-Y.; Kim, J.Y.; Hwang, M.; Lee, E.-H.; Choi, H.; Lee, K.-Y.; Lee, Y.J.; Koh, S.-H. Atorvastatin Rejuvenates Neural Stem Cells Injured by Oxygen–Glucose Deprivation and Induces Neuronal Differentiation Through Activating the PI3K/Akt and ERK Pathways. *Mol. Neurobiol.* **2019**, *56*, 2964–2977. [[CrossRef](#)]